Aspartylglucosamine

{{chembox

| Verifiedfields = changed

| verifiedrevid = 477350876

| ImageFile=Aspartylglucosamine.png

| ImageSize=200px

| IUPACName=(2S)-4-[[(2R,3R,4R,5S,6R)-3-Acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-2-amino-4-oxobutanoic acid

| OtherNames=

|Section1={{Chembox Identifiers

| CASNo_Ref = {{cascite|correct|CAS}}

| CASNo=2776-93-4

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = Q9ODP9B8O5

| ChEBI_Ref = {{ebicite|correct|EBI}}

| ChEBI = 58080

| PubChem=123826

| SMILES=CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1NC(=O)C[C@@H](C(=O)O)N)CO)O)O

| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}

| ChemSpiderID = 110370

| InChI = 1/C12H21N3O8/c1-4(17)14-8-10(20)9(19)6(3-16)23-11(8)15-7(18)2-5(13)12(21)22/h5-6,8-11,16,19-20H,2-3,13H2,1H3,(H,14,17)(H,15,18)(H,21,22)/t5-,6+,8+,9+,10+,11+/m0/s1

| InChIKey = YTTRPBWEMMPYSW-HRRFRDKFBT

| StdInChI_Ref = {{stdinchicite|correct|chemspider}}

| StdInChI = 1S/C12H21N3O8/c1-4(17)14-8-10(20)9(19)6(3-16)23-11(8)15-7(18)2-5(13)12(21)22/h5-6,8-11,16,19-20H,2-3,13H2,1H3,(H,14,17)(H,15,18)(H,21,22)/t5-,6+,8+,9+,10+,11+/m0/s1

| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}

| StdInChIKey = YTTRPBWEMMPYSW-HRRFRDKFSA-N

| MeSHName=N-acetylglucosaminylasparagine

}}

|Section2={{Chembox Properties

| Formula=C₁₂H₂₁N₃O₈

| MolarMass=335.31 g/mol

| Appearance=

| Density=

| MeltingPt=

| BoilingPt=

| Solubility=

}}

|Section3={{Chembox Hazards

| MainHazards=

| FlashPt=

| AutoignitionPt =

}}

}}

Aspartylglucosamine{{Cite web |last=PubChem |title=N-aspartylglucosamine |url=https://pubchem.ncbi.nlm.nih.gov/compound/134129131 |access-date=2023-01-13 |website=pubchem.ncbi.nlm.nih.gov |language=en}} is a derivative of aspartic acid.

Levels are elevated in aspartylglucosaminuria.{{Cite web |title=Aspartylglucosaminuria i |url=http://www.ismrd.org/the_diseases/aspartylglucosaminuria |publisher=ISMRD — The International Advocate for Glycoprotein Storage Diseases}}